Diabetes

Patients with diabetes are significantly more likely to develop cardiovascular disease than nondiabetic patients.

The FDA issued approval to semaglutide injection (Ozempic) for type 2 diabetes.

The FDA has approved Novo Nordisk’s semaglutide injection (Ozempic), a glucagon-like peptide 1 (GLP-1) receptor agonist, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Between 10% and 20% of students in kindergarten through high school have chronic illness.

Nearly 700 million individuals around the world will develop diabetes by 2045, many of whom are undiagnosed.

Women with type 2 diabetes were 43% more likely to develop estrogen receptor negative breast cancer than patients without diabetes.

Top articles of the week from The American Journal of Pharmacy Benefits.

A look at last week's top stories in the world of pharmacy.

Patients with severe psoriasis were 64% more likely to develop diabetes than control patients.

Children and young adults with diabetes 8 times more likely to experience cardiovascular mortality.

It’s been more than 6 decades since Professor R. Keith Campbell, from Washington State University, was diagnosed with diabetes.

Reducing calorie intake may reverse type 2 diabetes.

Advances in technology can guide insulin regimens prescribed at discharge among patients with diabetes.

High levels of weekly exercise slashed premature mortality risk in half for patients with type 1 diabetes.

What do pharmacists need to know about these mobile applications recently approved by the FDA?

November is diabetes awareness month, and pharmacists are excellent resources for patients who have this chronic condition.

Top articles of the week from The American Journal of Pharmacy Benefits.

Less than half of diabetic foot ulcers heal within 1 year.

Numerous immune cells may be involved with type 2 diabetes, according to a session presented at the at the American College of Rheumatology Annual Meeting.

Patients who engage in lifestyle changes can effectively prevent or at least delay a lifelong, chronic disease.

In a review of publicly reported diabetes quality measures for Medicaid fee-for-service, overall reporting was low and reports of outcomes measures were rarely available.

Empagliflozin (Jardiance) reduced the risk of cardiovascular mortality by 43% in patients with type 2 diabetes and peripheral artery disease.

Semaglutide treatment sparked an average weight loss of 11 pounds over 12 weeks.

When pharmacists promote behavioral changes, it encourages positive patterns that last a lifetime.

Does this antihyperglycemic combination medication need to be added to a formulary?